In the U.S., the five-year survival rate for all cancers combined has reached an historic milestone: it is now 70% for people diagnosed during 2015–2021, according to the American Cancer Society’s Cancer Statistics, 2026 report.
“Seven in 10 people now survive their Cancer five years or more, up from only half in the mid-70s,” said Rebecca Siegel, lead author of the report. “This stunning victory is largely the result of decades of cancer research that provided clinicians with the tools to treat the disease more effectively, turning many cancers from a death sentence into a chronic disease.”
While his doesn’t mean “70% are cured,” and it certainly doesn’t mean cancer is “solved,” it does mean more people are living longer—and more people are living with cancer as a chronic, managed condition.
Let’s dig into the science and what’s powering the shift across diagnosis and treatment for a disease that is a leading cause of death globally.
One of the biggest reasons the survival rate is improving is also one of the simplest: we’re catching cancers earlier, when they’re easier to treat.
Classic screening tools—mammograms, colonoscopies, cervical screening, low-dose CT scans for high-risk lung cancer—are still the backbone of prevention and early diagnosis. But what’s different now is how Technology is improving those tools.
Artificial Intelligence is becoming a quiet partner in medical imaging. It’s not replacing radiologists, but it can act like a second set of eyes, helping flag subtle findings that might otherwise be missed. A large Swedish trial published in The Lancet Digital Health found that AI-supported mammography improved detection and reduced interval cancers—those cancers that appear between routine screenings and often carry worse outcomes.
Then there’s the new blood tests. You may have heard about “liquid biopsies” or multi-cancer early detection tests—blood tests designed to pick up tiny fragments of tumor DNA circulating in the bloodstream. The idea is certainly compelling: what if we could find cancers early with a simple blood draw, even cancers that don’t have good screening tools today?
Early studies are encouraging. One of the largest ongoing efforts, GRAIL’s PATHFINDER 2 study, has reported that adding a multi-cancer blood test to standard screening found more cancers than screening alone.
It’s important to note, however, that finding more cancers does not automatically mean saving more lives. These tests still need to prove they reduce mortality and don’t unintentionally create harm through false positives, unnecessary procedures, or over diagnosis. It’s one of the most exciting areas in cancer science—but it’s also one of the most carefully debated.
For many people, “cancer treatment” still brings to mind chemotherapy, which can be exhausting, harsh, and indiscriminate. And chemo is still used widely, often very effectively. But the modern cancer toolbox is bigger than most people realize.
One of the biggest breakthroughs in recent years has been a class of drugs called antibody–drug conjugates, or ADCs. Think of them as targeted delivery systems: an antibody guides the drug to cancer cells, and a potent payload does the damage. The goal is to hit cancer harder while sparing more healthy tissue.
A standout example is trastuzumab deruxtecan (Enhertu), which has expanded beyond its original use in HER2-positive breast cancer into HER2-positive solid tumors more broadly.
Another major shift is what some refer to as “living medicine”—cellular therapies like CAR-T. CAR-T Therapy takes a patient’s own immune cells, re-engineers them to recognize cancer, and sends them back into the body, much like a guided missile. In certain blood cancers, including some leukemias, lymphomas, and multiple myeloma, CAR-T has changed what’s possible for patients who previously had few options.
And then there’s the word that keeps popping up in the news: vaccines. Not the prevention vaccines that have already made a big difference—like the HPV vaccine, which helps prevent cervical and other cancers—but therapeutic cancer vaccines designed to train the immune system to recognize an individual person’s tumor.
One of the most closely watched examples is a personalized mRNA cancer vaccine paired with immunotherapy in high-risk melanoma. In a phase 2 study published in The Lancet, the combination improved recurrence-free survival compared with immunotherapy alone.
This doesn’t mean cancer vaccines are “here” in the everyday way flu shots are. But it does suggest we’re entering a period where the immune system can be coached with much more precision than ever before.
While this progress from modern cancer science is exciting, unfortunately, it doesn’t always reach everyone equally. Access to screening and specialists, the ability to afford advanced therapies, even the time and transportation required to keep appointments—these factors shape outcomes as much as biology does. The American Cancer Society has emphasized that much still needs to be done to address disparities across race, geography, and income, even as overall survival improves.
When people say that “cancer is becoming a manageable condition,” they’re pointing to something real: many cancers can now be treated in ways that extend life for years, sometimes with long periods of stability. In some cases, cancer begins to look more like a chronic illness—something monitored, adjusted, treated in phases, and lived alongside.
But it’s also important to keep in mind that cancer isn’t one disease, and it doesn’t behave the same way. Some cancers are still aggressive and difficult to treat. Others are caught late because symptoms are vague or screening is limited. And even when treatments work, they can leave behind lasting effects—fatigue, neuropathy, cognitive changes, cardiac risks, and emotional aftershocks that linger long after remission.
This is where survivorship becomes its own chapter of medicine.
More people living longer means more people needing support through the “after”—the years of follow-up scans, medication management, and recovery that can feel like a second journey. For older adults especially, survivorship care often blends into other aspects of healthy Aging: strength, mobility, nutrition, memory, independence, and quality of life.
We’re moving from treating cancer as a single catastrophic event to treating it as a measurable, increasingly targetable condition—one that more people can survive, and many can live with.
That shift is being powered by earlier detection, smarter imaging, precision drugs, immune-based therapies, and a growing recognition that survival is about more than just living longer—it’s about living better.
For older adults, these advances are especially meaningful because cancer risk rises with age—and so does the importance of preserving function, independence, and quality of life. Earlier detection may allow for less intensive treatment and better outcomes, while newer targeted and immune-based therapies can offer options even for patients who once might not have tolerated aggressive chemotherapy.
At the same time, survivorship is increasingly a long-term journey: managing side effects, monitoring for recurrence, and supporting the whole person—not just the tumor.
The main takeaway, however, is certainly a positive one: cancer care is becoming more personalized, more precise, and more focused on helping people live well for longer.
Focused ultrasound holds promise for treating cancer, Alzheimer’s and other diseases
New study: COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
Nobel medicine prize: How a hidden army in your body keeps you alive – and could help treat cancer
It’s called the vagus nerve – and it just might be a game-changer in fighting age-related disease
A blood test that screens for multiple cancers at once promises to boost early detection
Power foods that help to fight cancer
Content on this site is for informational purposes only and is not a substitute for professional medical advice. Always check with your qualified healthcare providers with any questions or concerns regarding a medical condition.
